search
Back to results

Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation (HD-WACA)

Primary Purpose

Atrial Fibrillation

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Atrial Fibrillation Ablation
Catheters used to isolate pulmonary veins
Atrial Fibrillation Ablation with HD mapping to isolate PVs
Rhythmia HD mapping
Sponsored by
Imperial College Healthcare NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring Atrial Fibrillation

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ECG documented AF
  • Listed for AF ablation by referring physician
  • Planned ablation includes a first-time PVI.
  • Patient signed informed consent form

Exclusion Criteria:

  • Age <18 or >80
  • LA diameter >60mm
  • AF secondary to transient correctible abnormalits (e.g. electrolyte imbalance, thyrotoxicosis, recent infective or inflammatory process)
  • Intra-atrial thrombus or tumour
  • Renal failure requiring haemodialysis
  • Heart failure with NYHA III-IV or EF<35%

Sites / Locations

  • Hammersmith Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Group A - Standard Care

Group B - Rhythmia mapping

Arm Description

The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.

The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.

Outcomes

Primary Outcome Measures

Total time in minutes required to produce isolation of veins per WACA
Following first pass ablation with WACA, if either vein is not isolated the patient will be randomized into group A or B. The total RF time taken to isolate the veins for that WACA will be measured as one of 2 joint primary outcome measures.
Total number of radiofrequency ablation lesions to produce isolation of veins per WACA
Following first pass ablation with WACA, if either vein is not isolated the patient will be randomized into group A or B. The total number of lesions (each lesion being 30s in duration) to isolate the veins for that WACA will be measured as one of two joint primary outcome measures.

Secondary Outcome Measures

Whether ostial ablation is required in each case (Yes/No)
This is a measure of whether ostial ablation (undesirable) will be required (yes/no). It is assessed during procedure.
Number of radiofrequency ablation lesions required within the WACA lesion set
The number of oostial lesions required in each case (number of ablation lesions)
Total radiofrequency ablation time (in mins) within the WACA lesion set
This is the total ablation time (in mins) within the WACA required to produce PV isolation
Total number of radiofrequency ablation lesions required to produce PV isolation per patient
As per primary endpoint but on a per patient rather than per vein basis
Total procedural time (in mins) required to produce PV isolation
Whether procedure time (in mins) is different in group A vs group B
Percentage of patients with successful PV isolation
Proportion of veins successfully isolated with the contrasting techniques
Percentage of patients suffering symptomatic PV stenosis
Proportion of patients coming back within 3 months with symptomatic PV stenosis
Percentage of patients with AF recurrence
Proportion of patients remaining AF free at 3 months as analysed per Kaplan-Meier format

Full Information

First Posted
August 5, 2016
Last Updated
October 4, 2019
Sponsor
Imperial College Healthcare NHS Trust
Collaborators
Boston Scientific Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT02917044
Brief Title
Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation
Acronym
HD-WACA
Official Title
Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Terminated
Why Stopped
Recruitment issues due to competing studies. Higher than expected PVI on first pass. Sample would have to be increased which was not feasible.
Study Start Date
March 2016 (Actual)
Primary Completion Date
March 2018 (Actual)
Study Completion Date
June 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College Healthcare NHS Trust
Collaborators
Boston Scientific Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, multicentre, randomized single blind, parallel group study to be conducted in the UK (2 sites).Approximately 48 patients will be recruited aiming for 40 eligible for randomization. The study is designed to compare the operator's best attempt at WACA completion with and without Rhythmia guidance
Detailed Description
BACKGROUND Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia occurring in 1-2% of the general population. AF can be associated with debilitating symptoms and confers an increased risk of death, stroke, heart failure and hospitalization. As such there is a need for effective therapies for AF. In particularly catheter based therapies, which can limit the need for chronic drug therapy, are becoming more widely accepted. The development of AF requires both a trigger and susceptible substrate. Ectopic activity originating within the pulmonary veins (PVs) is a widely recognised factor in the genesis of paroxysmal AF, whilst electrical, contractile and structural remodelling of atrial myocardium are each important contributing factors to the arrhythmogenic substrate in AF. An early strategy in paroxysmal AF (PAF) was to target ectopic triggers coming from the PV via ostial segmental ablation (OSA). Here radiofrequency (RF) ablation was applied close to the PV ostia at sites of early signals, usually until PVs were electrically isolated from the left atrium (LA). This approach resulted in a success rate, with regard to freedom from AF after a single procedure, of 65-90% after 1 year but closer to 50% after 5 years. The recognition of PV stenosis as a complication of RF delivery within a PV, as well as the recognition that initiation sites could be located in the antrum led to a shift in ablation strategy towards wider encirclement of the PVs using wide area circumferential ablation (WACA) using electroanatomical mapping to guide RF delivery. This resulted in improved success rates in a head-to-head comparison with OSA and it is possible that this relates to substrate modification inherent in this approach. Recurrence of AF remains problematic following ablation. Pulmonary vein reconnection after ablation is thought to contribute to the majority of recurrent episodes of AF in paroxysmal AF. Electrical isolation of the PVs is often not achievable with WACA alone - 95% of patients had residual connections following WACA alone in one study. Most clinicians at this juncture will look for any obvious gaps in the line and ablate if there are early PV signals. If this is unsuccessful then it is often necessary to resort to OSA to achieve PV isolation. In essence a large proportion of PV isolation procedures, which started with a WACA strategy, are in fact a hybrid of WACA and OSA. This both has the potential to increase the complication rate by risking PV stenosis and reducing efficacy through omitting important substrate modification and allowing residual connection of part of the antrum and the LA. The introduction of Rhythmia, a novel electroanatomical mapping system with the potential to rapidly acquire high density electroanatomical data, may allow an alternative strategy and more efficient targeting of gaps in WACA lines. The pilot data shows that the system is particularly adept in assessing gaps in ablation lines including WACA lines. Mapping and targeting such gaps may hold the key to efficiently completing PV isolation after an initial WACA line is performed. RATIONALE FOR CURRENT STUDY Research Question: Can ostial segmental ablation be avoided during a wide area circumferential ablation (WACA) by using the Rhythmia high density mapping system? Hypothesis: The current study is designed to test the hypothesis that high density mapping using Rhythmia can enhance the operator's ability to electrically isolate PVs without unnecessary excessive ablation or OSA

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
Atrial Fibrillation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A - Standard Care
Arm Type
Active Comparator
Arm Description
The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
Arm Title
Group B - Rhythmia mapping
Arm Type
Experimental
Arm Description
The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
Intervention Type
Procedure
Intervention Name(s)
Atrial Fibrillation Ablation
Intervention Description
Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
Intervention Type
Device
Intervention Name(s)
Catheters used to isolate pulmonary veins
Intervention Description
Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
Intervention Type
Procedure
Intervention Name(s)
Atrial Fibrillation Ablation with HD mapping to isolate PVs
Intervention Description
Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
Intervention Type
Device
Intervention Name(s)
Rhythmia HD mapping
Intervention Description
Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
Primary Outcome Measure Information:
Title
Total time in minutes required to produce isolation of veins per WACA
Description
Following first pass ablation with WACA, if either vein is not isolated the patient will be randomized into group A or B. The total RF time taken to isolate the veins for that WACA will be measured as one of 2 joint primary outcome measures.
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Title
Total number of radiofrequency ablation lesions to produce isolation of veins per WACA
Description
Following first pass ablation with WACA, if either vein is not isolated the patient will be randomized into group A or B. The total number of lesions (each lesion being 30s in duration) to isolate the veins for that WACA will be measured as one of two joint primary outcome measures.
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Secondary Outcome Measure Information:
Title
Whether ostial ablation is required in each case (Yes/No)
Description
This is a measure of whether ostial ablation (undesirable) will be required (yes/no). It is assessed during procedure.
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Title
Number of radiofrequency ablation lesions required within the WACA lesion set
Description
The number of oostial lesions required in each case (number of ablation lesions)
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Title
Total radiofrequency ablation time (in mins) within the WACA lesion set
Description
This is the total ablation time (in mins) within the WACA required to produce PV isolation
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Title
Total number of radiofrequency ablation lesions required to produce PV isolation per patient
Description
As per primary endpoint but on a per patient rather than per vein basis
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Title
Total procedural time (in mins) required to produce PV isolation
Description
Whether procedure time (in mins) is different in group A vs group B
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Title
Percentage of patients with successful PV isolation
Description
Proportion of veins successfully isolated with the contrasting techniques
Time Frame
Procedural - i.e. assessed over procedure duration only (about 3 hours)
Title
Percentage of patients suffering symptomatic PV stenosis
Description
Proportion of patients coming back within 3 months with symptomatic PV stenosis
Time Frame
3 months
Title
Percentage of patients with AF recurrence
Description
Proportion of patients remaining AF free at 3 months as analysed per Kaplan-Meier format
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ECG documented AF Listed for AF ablation by referring physician Planned ablation includes a first-time PVI. Patient signed informed consent form Exclusion Criteria: Age <18 or >80 LA diameter >60mm AF secondary to transient correctible abnormalits (e.g. electrolyte imbalance, thyrotoxicosis, recent infective or inflammatory process) Intra-atrial thrombus or tumour Renal failure requiring haemodialysis Heart failure with NYHA III-IV or EF<35%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boon Lim
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hammersmith Hospital
City
London
State/Province
Please Select Region, State Or Province
ZIP/Postal Code
W120HS
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation

We'll reach out to this number within 24 hrs